These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1577054)

  • 1. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects.
    Nakashima M; Uematsu T; Kosuge K; Kanamaru M
    Eur J Clin Pharmacol; 1992; 42(3):333-5. PubMed ID: 1577054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects.
    Burnier M; Rutschmann B; Nussberger J; Versaggi J; Shahinfar S; Waeber B; Brunner HR
    Hypertension; 1993 Sep; 22(3):339-47. PubMed ID: 8349327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers.
    De Smet M; Schoors DF; De Meyer G; Verbesselt R; Goldberg MR; Fitzpatrick V; Somers G
    Br J Clin Pharmacol; 1995 Dec; 40(6):571-5. PubMed ID: 8703664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.
    Goldberg MR; Tanaka W; Barchowsky A; Bradstreet TE; McCrea J; Lo MW; McWilliams EJ; Bjornsson TD
    Hypertension; 1993 May; 21(5):704-13. PubMed ID: 8491505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension.
    Sasaki M; Fujimura A; Harada K; Sunaga K; Ebihara A
    J Clin Pharmacol; 1996 May; 36(5):403-8. PubMed ID: 8739018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.
    Christen Y; Waeber B; Nussberger J; Porchet M; Borland RM; Lee RJ; Maggon K; Shum L; Timmermans PB; Brunner HR
    Circulation; 1991 Apr; 83(4):1333-42. PubMed ID: 2013151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-response relationships following oral administration of DuP 753 to normal humans.
    Christen Y; Waeber B; Nussberger J; Lee RJ; Timmermans PB; Brunner HR
    Am J Hypertens; 1991 Apr; 4(4 Pt 2):350S-353S. PubMed ID: 1854464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan.
    Goldberg MR; Lo MW; Christ DD; Chiou R; Furtek CI; Amit O; Carides A; Biollaz J; Piguet V; Nussberger J; Brunner HR
    Clin Pharmacol Ther; 1997 Jan; 61(1):59-69. PubMed ID: 9024174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of losartan on renal function in patients with essential hypertension.
    Fauvel JP; Velon S; Berra N; Pozet N; Madonna O; Zech P; Laville M
    J Cardiovasc Pharmacol; 1996 Aug; 28(2):259-63. PubMed ID: 8856482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
    Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
    Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the nonpeptide angiotensin II receptor antagonist DuP 753 on blood pressure and renal functions in spontaneously hypertensive PH dogs.
    Bovee KC; Wong PC; Timmermans PB; Thoolen MJ
    Am J Hypertens; 1991 Apr; 4(4 Pt 2):327S-333S. PubMed ID: 1854460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats.
    Tofovic SP; Pong AS; Jackson EK
    Hypertension; 1991 Dec; 18(6):774-82. PubMed ID: 1743758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist.
    Munafo A; Christen Y; Nussberger J; Shum LY; Borland RM; Lee RJ; Waeber B; Biollaz J; Brunner HR
    Clin Pharmacol Ther; 1992 May; 51(5):513-21. PubMed ID: 1587065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DuP 753, a nonpeptide angiotensin II-1 receptor antagonist, alters dopaminergic function in rat striatum.
    Dwoskin LP; Jewell AL; Cassis LA
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Feb; 345(2):153-9. PubMed ID: 1314959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drinking induced by subcutaneous injection of angiotensin II in the rat is blocked by the selective AT1 receptor antagonist DuP 753 but not by the selective AT2 receptor antagonist WL 19.
    Dourish CT; Duggan JA; Banks RJ
    Eur J Pharmacol; 1992 Jan; 211(1):113-6. PubMed ID: 1618259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man.
    Doig JK; MacFadyen RJ; Sweet CS; Lees KR; Reid JL
    J Cardiovasc Pharmacol; 1993 May; 21(5):732-8. PubMed ID: 7685442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.
    Goldberg MR; Bradstreet TE; McWilliams EJ; Tanaka WK; Lipert S; Bjornsson TD; Waldman SA; Osborne B; Pivadori L; Lewis G
    Hypertension; 1995 Jan; 25(1):37-46. PubMed ID: 7843751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.
    Tsunoda K; Abe K; Hagino T; Omata K; Misawa S; Imai Y; Yoshinaga K
    Am J Hypertens; 1993 Jan; 6(1):28-32. PubMed ID: 8427658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension.
    Smith MC; Barrows S; Meibohm A; Shahinfar S; Simpson RL; Weigel K; Dunn MJ
    Am J Hypertens; 1995 Dec; 8(12 Pt 1):1177-83. PubMed ID: 8998251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a nonpeptide angiotensin II receptor antagonist, DuP 753, on angiotensin-related water intake in rats.
    Fregly MJ; Rowland NE
    Brain Res Bull; 1991 Jul; 27(1):97-100. PubMed ID: 1933441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.